Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage

Journal of Hypertension

Volumn 27, Issue 12, 2009, Pages 2444-2451

  Gelosa, Paolo ^a   Pignieri, Alice ^a   Fä, Lars ^c   De Gasparo, Marc ^d   Hallberg, Anders ^e   Banfi, Cristina ^b   Castiglioni, Laura ^a   Turolo, Lucia ^a   Guerrini, Uliano ^a   Tremoli, Elena ^a,b   Sironi, Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d MG Consulting Co   (Switzerland)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiotensin type 2 receptor; Fibrosis; Inflammation; Kidney; Stroke prone rats

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACUTE PHASE PROTEIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR AGONIST; COLLAGEN; COMPOUND 21; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; BRAIN DAMAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HIGH SODIUM INTAKE; INFLAMMATORY INFILTRATE; KIDNEY INJURY; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 73649119592     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283311ba1     Document Type: Article

References (37)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin Il receptors. Pharmacol Rev 2000; 52:415-472.
2. Ruilope LM, Rosei EA, Bakris GL, Maneia G, Poulter NR, Taddei S, ef al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005; 14:196-209. (Pubitemid 41387809)
3. de Gasparo M, Siragy HM. The AT2 receptor: fact, fancy and fantasy. Regul Pept 1999; 81:11-24.
4. Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005; 45:133-137. (Pubitemid 40066427)
5. Steckelings UM, Kaschina E, Unger T. The AT2 receptor: a matter of love and hate. Peptides 2005; 26:1401-1409. (Pubitemid 41021474)
6. Ardaillou R. Angiotensin Il type Il receptor. Does it have a role in the normal or diseased kidney? Nephrol Dial Transplant 1994; 9:1364-1365. (Pubitemid 24310273)
7. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin IImediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34. (Pubitemid 30127593)
8. Ruiz-Ortega M, Rupérez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006; 21:16-20. (Pubitemid 43057101)
9. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. JAm Soc Nephrol 2004; 15:1514-1529. (Pubitemid 38679676)
10. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, et al. Angiotensin Il stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997; 100:1047-1058. (Pubitemid 27386288)
11. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin Il activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002; 61:1986-1995.
12. Wu L, Iwai M, Nakagaml H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammationinduced vascular injury. Circulation 2001; 104:2716-2721. (Pubitemid 33108140)
13. Wu L, Iwai M, Li Z, Shiuchl T, Min U, Cui TX, ef al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol 2004; 18:666-678. (Pubitemid 38328210)
14. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2000; 2:13-20.
15. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, et al. Overexpression of angiotensin Il type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and hemeoxygenase-1 expression. Atherosclerosis 2008; 199:288-294.
16. Sironi L, Tremoli E, Miller I, Guerrinl U, Calvio AM, Eberini I, et al. Acutephase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Sfrote 2001; 32:753-760.
17. Sironi L, Gelosa P, Guerrin U, Banfi C, Crippa V, Brioschi M, et al. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004; 311:989-995. (Pubitemid 39612703)
18. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin Il type 2 receptor research in the cardiovascular system. Hypertension 1999; 33:613-621. (Pubitemid 29091636)
19. Wan Y. Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47:5995-6008. (Pubitemid 39507341)
20. Breohler V, Jones PW, Levens NR, de Gasparo M, Bottari SP. Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. Regul Pept 1993; 44:207-213. (Pubitemid 23083368)
21. Macari D, Whitebread S, Cumin F, de Gasparo M, Levens N. Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 1994; 259:27-36. (Pubitemid 24193189)
22. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis instroke-prone rats. Am J Pathol 2007; 170:1165-1177. (Pubitemid 47339325)
23. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements In low renin hypertensive states. Trends Endocrinol Metab 2005;16:86-91. (Pubitemid 40432456)
24. Richer C, Vacher E, Fornes P, Giudicelli JF. Antihypertensive drugs in the stroke-prone spontaneously hypertensive rat. Clin Exp Hypertens 1997; 19:925-936. (Pubitemid 27321714)
25. Kyselovic J, Krenek P, Wibo M, Godfraind T. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br J Pharmacol 2001; 134:1516-1522. (Pubitemid 33131902)
26. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009; 40:1482-1489.
27. Savoia C, Ebrahimlan T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMPdependent protein kinase. J Hypertens 2006; 24:2417-2422. (Pubitemid 44684690)
28. Rompe F, Hallberg A, Alterman M, Artuc M, Bader M, Schwaninger M, et al. The first selective nonpeptide angiotensin AT2-receptor agonist Compound 21 attenuates TNFa-induced IL-6 expression through inhibition of NF-kB activity [Abstract]. J Hypertens 2008; 26(Suppl 1): PS25/THU/38.
29. Ströder K, Rompe F, Reichenbach A, Thöne-Relneke C, Artuc M, Hallberg A, et al. Direct angiotensin AT2 receptor Stimulation by the novel nonpeptide Compound 21 acts anti-inflammatory and antiflbrotic in a mouse model of scleroderma activity [Abstract]. J Hypertens 2008; 26(Suppl 1):PS25/THU/57.
30. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial Infarction? Circulation 2008; 118:2523-2532.
31. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116:263-272. (Pubitemid 38224234)
32. Siragy HM, lnagami T, Carey RM. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul lntegr Comp Physiol 2007; 293:R1461-R1467.
33. lchihara A, Hayashi M, Hirota N, Okada H, Koura Y, Tada Y, et al. Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertens Res 2003; 26:915-921.
34. Jia N, Okamoto H, Shimizu T, Chiba S, Matsui Y, Sugawara T, et al. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression. Hypertens Res 2003; 26:737-742. (Pubitemid 37258662)
35. Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Böhm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension 1998;31:1272-1277. (Pubitemid 28248827)
36. Gonzalez M, Lobos L, Castillo F, Galleguillos L, Lopez NC, Michea L. Highsalt diet inhibits expression of angiotensin type 2 receptor in resistance arteries. Hypertension 2005; 46:853-859. (Pubitemid 40628928)
37. Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, Denton KM. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension 2008; 52:666-671.